ArticleCell death & disease2025
Th17-like cells and immunosuppressive macrophages infiltrate tertiary lymphoid structures with distinct maturation status in soft-tissue sarcoma.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research landscape and emerging trends of tertiary lymphoid structures in autoimmune diseases: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- Tertiary lymphoid structures in cancer: their development, composition, clinical prognosis, and the drivers of the anti-tumor responses.Molecular biomedicine · 2026Review
- Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context.Cancers · 2026Review
- Review
- The evolving role of the immune microenvironment of tumor draining lymph nodes in the development of biomarkers of non-small cell lung cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLSs) have been associated with favorable clinical outcome and improved responses to immune checkpoint inhibitors in soft-tissue sarcomas (STSs). However, due to their rarity and high heterogeneity, information regarding the mechanisms involved in TLS formation and contribution to antitumor immunity in STS are extremely elusive. To address this gap, we integrated immunohistochemistry and transcriptomic analyses from 31 treatment-naïve STS specimens from an independent cohort of patients with primary or locally recurrent disease. Further validation was conducted using external bulk, single-cell and spatial transcriptomics data from 5 publicly available datasets. We found TLSs to be highly heterogeneous in terms of amount, localization, maturation status and cellular composition, and corroborated previous findings showing that their presence, along with B cells in the STS microenvironment, are good indicators of favorable prognosis. Transcriptomic analysis showed that high expression of germinal center (GC) B cell-related genes was associated with TLS presence and with an upregulation of signatures specific for T helper 17 (Th17) cells in STS and other cancer types. Conversely, genes signatures discriminating for immunosuppressive M2-like macrophages were enriched in tumors with low expression of GC B cell-related genes. Immunohistochemistry showed distinct spatial patterns for Th17-like cells and M2-like macrophages within TLS areas, with IL17A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.